


R&D pipeline







Updated since Dec. 31, 2024



Clinical study is being conducted in JP, NA, EU, Asia,

and Oceania as a global product

As of Jun. 30, 2025 Stage [In-House or Licensed] **Generic Name Mechanism of Action** Indication Remarks Formulation PhT PhII PhIII [In-House] KK8123 Anti-FGF23 Fully Human Y_linked Clinical study is being conducted in NA and EU as a Injection Antibody Hypophosphatemia global product KK8398 [QED Therapeutics] * infigratinib FGFR 3 Inhibitor Achondroplasia Preparation underway for Ph Ⅲ in JP Oral [Kura Oncology] The detailed results presented at ASCO in June 2025 Acute Myeloid Leukemia Adult Relapsed or Refractory AML with a NPM1 (AML) (Monotherapy) Mutation KOMET-001 Clinical study is being conducted in NA and EU as a Acute Lymphoblastic global product Leukemia (ALL) KMT2A-rearranged ALL (Monotherapy) KOMET-001 Clinical study is being conducted in NA and EU as a Acute Myeloid Leukemia global product (AML) Non-NPM1-mutant AML/Non-KMT2A-rearranged AML (Monotherapy) 济 ziftomenib ※ KOMFT-001 Menin Inhibitor Oral Clinical study is being conducted in NA as a global NPM1-mutant AML/KMT2A-rearranged AML Combinations with venetoclax + azacitidine, and cytarabine + daunorubicin KOMET-007 Clinical study is being conducted in NA and EU as a Acute Myeloid Leukemia global product (AML) NPM1-mutant AML/KMT2A-rearranged AML (Combination) Combinations with gilteritinib, FLAG-IDA, LDAC KOMET-008 Preparation underway for Ph III as a global product NPM1-mutant AML/KMT2A-rearranged AML Combinations with venetoclax + azacitidine, and cytarabine + daunorubicin KOMET-017 [In-House] Acute Myeloid Leukemia Antibody-Drug Conjugate KK2845 Anti-TIM-3 ADC Clinical study is being conducted in JP as a global (AML) product [In-House] Rare Pediatric Disease (RPD) and Fast Track Hematopoietic Stem Cell OTL-203 MPS-IH (Hurler Syndrome) designations (FDA) (HSC) Gene Therapy Priority Medicines (PRIME) designation (EMA) Area of clinical study: NA and EU [In-House] MPS-IIIA (Sanfilippo Hematopoietic Stem Cell Rare Pediatric Disease (RPD) designation (FDA) OTL-201 Syndrome type Preparation underway for registrational study (HSC) Gene Therapy Ph I / (equivalent to PhⅢ study) Ph II [In-House] POTELLIGENT Human monoclonal antibody production technology Collaboration agreement with Amgen for the Moderate to Severe Atopic development of rocatinlimab in all the countries Dermatitis except for Japan Clinical study is being conducted in JP, NA, EU, UK, KHK4083/AMG 451 Middle East, Asia, Oceania, and other regions as a rocatinlimab Anti-OX40 Antibody global product Injection Clinical study is being conducted in JP, NA, EU, Asia, Prurigo Nodularis and Oceania as a global product

Moderate to Severe

[※] For detailed information on ziftomenib's development status, please refer to Kura Oncology's website. https://kuraoncology.com/



| Code Name | | Machanian of Astron | Indication | Stage | | | [In-House or Licensed] |
|-----------|------------------------------------|--------------------------------------------|------------------------------------------------------------------|----------|------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | Generic Name Formulation | Mechanism of Action | Indication | PhI | PhII | PhIII | Remarks |
| X | KHK4951 tivozanib Ophthalmic | VEGF Receptor Tyrosine Kinase Inhibitor | Diabetic Macular Edema | | | | [In-House] Clinical study is being conducted in JP, NA, Asia, and Oceania as a global product |
| | | | Neovascular Age-Related Macular Degeneration | | | | Clinical study is being conducted in JP, NA, Asia, and Oceania as a global product |
| ¥ | KK2260 Injection | EGFR-TfR1Bispecific Antibody | Advanced or Metastatic Solid Tumors | | | | [In-House] REGULGENT Fully human antibody production technology Clinical study is being conducted in JP, and a clinical study is prepared under way for PhI in NA as a global product |
| ¥ | KK2269 Injection | EpCAM-CD40Bispecific Antibody | Advanced or Metastatic Solid Tumors | | | | [In-House] REGULGENT Fully human antibody production technology Clinical study is being conducted in JP and NA as a global product |
| * | KK4277 Injection | Anti-PTPRS Humanized Antibody | Systemic Lupus Erythematosus/Cutaneous Lupus Erythematosus | | | | [SBI Biotech] POTELLIGENT Clinical study is being conducted in JP and Asia |
| * | KK3910 Injection | | Essential Hypertension | ✓ | | | [In-House] Clinical study is being conducted in JP as a global product |

Major Applications and Approvals

As of Jun 30, 2025

| Code Name, Generic Name, Product Name | Indication | Application/Under Review | Countries/Regions Received Approval in 2025 |
|-----------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|--------------------------|---------------------------------------------------|
| ziftomenib | Adult Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) with a Nucelophosmin1 (NPM1) Mutation | us | - |
| KHK4827(brodalumab, Product name in Japan and Asia: Lumicef) | Palmoplantar Pustulosis | - | TW |
| AMG531(romiplostim, Product name in Japan: Romiplate) | Aplastic Anemia | TW | = |